Navigation Links
TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Date:3/18/2008

LA JOLLA, Calif., March 18 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced it has initiated a Phase II study of NGX267, a muscarinic agonist in development for xerostomia, or dry mouth, secondary to Sjogren's syndrome.

The company is conducting a randomized, double-blind, placebo-controlled, cross-over study with a Latin square design to evaluate the safety, tolerability and efficacy of this once-a-day compound. Approximately 24 patients will be enrolled at three sites in the United States. In four distinct treatment periods, each patient will be randomized to receive a single dose of 10 mg, 15 mg and 20 mg of NGX267 and placebo. The order of treatment is determined by the Latin square design. The primary endpoint of the study is quantitative measure of salivary flow.

"As we previously announced, we are focusing our clinical development activities on maximizing the value of our lead compounds to take advantage of their versatility," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "Three Phase I studies have already demonstrated the safety and tolerability of NGX267. More importantly for patients suffering from xerostomia, two of these studies demonstrated statistically significant increases in salivary flow. We are well-positioned to advance NGX267 as a potential new treatment for xerostomia associated with Sjogren's syndrome."

In a Phase I multiple-dose study completed in September 2007, salivary flow increased linearly with doses of NGX267, and these increases were maintained over four days of dosing.

"Xerostomia is a hallmark symptom of Sjogren's syndrome, one of the most prevalent autoimmune disorders, striking as many as 4 million Amer
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
2. TorreyPines Therapeutics Reports Third Quarter 2007 Results
3. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
6. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
7. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
8. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
9. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
10. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
11. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four new ... and provides a good start to Q4.  The orders are for ... and one in the Middle East . ... Peter Bruijns , President & CEO. "Total bidding activity and ... have been for any complete year since the company has tracked ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The ... ABIM will take place at the Congress ... 2014 is now available at http://www.abim.ch ... and organizations from all over the globe ... the latest products and developments on the ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report ... with analysis and forecast of revenue. This market is ... $208 million by 2019, at a Compound Annual Growth ... Browse through the TOC of the Asia-Pacific Speech Analytics ... analysis provided. It also provides a glimpse of the ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... , PRINCETON, N.J., July 15 ... a license agreement with Merck KGaA, Darmstadt, Germany, providing the ... Technology platform for the research, development and commercialization of their ... , "We are extremely pleased ...
... July 14 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; ... and six months ended May 31, 2009. All dollar amounts ... At May 31, 2009, our cash and cash equivalents totaled ... Our net cash used in operating activities for the three ...
... , , , LAKE ... technology company focused on improving blood collection, separation, safety and ... agreement with Verax Biomedical Incorporated to market, sell and distribute ... used to detect bacterial contaminants in donated blood platelets. ...
Cached Biology Technology:BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA 2Vasogen Announces Second Quarter 2009 Results 2Vasogen Announces Second Quarter 2009 Results 3Vasogen Announces Second Quarter 2009 Results 4Vasogen Announces Second Quarter 2009 Results 5Vasogen Announces Second Quarter 2009 Results 6Vasogen Announces Second Quarter 2009 Results 7Vasogen Announces Second Quarter 2009 Results 8Vasogen Announces Second Quarter 2009 Results 9Vasogen Announces Second Quarter 2009 Results 10Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test 2Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test 3
(Date:10/14/2014)... – Scientists have sequenced the house fly genome for ... might expect from an insect that thrives in pathogen-rich ... Oct. 14 in the journal Genome Biology , ... and of how flies quickly adapt to resist insecticides, ... house flies (Musca domestica) carry and transmit more than ...
(Date:10/14/2014)... – October 14, 2014 – Scientists from The Scripps ... the National Institutes of Health (NIH) to lead an ... hemorrhagic fever disease in Africa. The study aims to ... some patients die, while others survive the inflection. ... the basic mechanism of how Lassa fever virus causes ...
(Date:10/14/2014)... October 14, 2014 – Over the past decades, we ... institutions to meet the needs of infants for social ... these infants to thrive. , Infancy and ... of the cortex. A generation of research suggests that ... cortical development and cognitive function. In contrast, deprivation and ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2Institutional rearing may increase risk attention-deficit disorder 2
... a team led by researchers from Caltech has for ... of chemoreceptorsthe receptors that sense and respond to chemical ... specific architecture is the same throughout a wide variety ... stable, universal structure that has been conserved over evolutionary ...
... new university/industry network to pursue the development of biomaterials, ... increasing incidence of eye disease. The 20/20: NSERC ... as part of the Natural Sciences and Engineering Research ... Minister of State (Science and Technology) Gary Goodyear today ...
... cell researcher Treena Livingston Arinzeh will discuss current stem cell ... for bone fracture and osteoarthritis treatments, spinal cord repair, and ... The event will be held Sept. 29, 2009, at ... floor of the NJIT Campus Center. The ...
Cached Biology News:Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 4New research network at McMaster aims to build a better eye 2
Request Info...
Designed for use with any of the Agencourt kits in tube format....
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... glass plates, bar clamp, and a built-in ... these units are:, safety interlock lids , ... upper and lower reservoirs have drains with ... of buffer solutions , leveling base with ...
Biology Products: